Platelet-Rich Plasma Therapy for Telogen Effluvium: A Comprehensive Evaluation of Efficacy and Safety

¹Department of Dermatology, Isra University Hyderabad, Pakistan

²Department of Pathology, People's University of Medical and Health Sciences for women, Isra University, Hyderabad, Pakistan

³Department of Biochemistry, Isra University Hyderabad, Pakistan

⁴Department of Physiology, Isra University Hyderabad, Pakistan

⁵Head of Medical Affairs, Helix Pharma, Karachi, Pakistan

⁶Medical Affairs, Helix Pharma, Karachi, Pakistan

*Corresponding Author: Uzma Dost Muhammad Rajar, Department of Dermatology, Isra University Hyderabad, Pakistan; Email: [email protected]

Received Date: February 26, 2024

Publication Date: March 20, 2024

Citation: Rajar UDM, et al. (2024). Platelet-Rich Plasma Therapy for Telogen Effluvium: A Comprehensive Evaluation of Efficacy and Safety. Dermis. 4(1):9.

Copyright : Rajar UDM, et al. © (2024).

ABSTRACT

Background: Chronic Telogen Effluvium (TE) is a common hair loss condition. This study explores the effectiveness of PRP and Tressfix Serum in treating Chronic TE. It aims to uncover potential therapeutic approaches through microRNA expression analysis. Objective: The objective is to evaluate the effectiveness and safety of combining platelet-rich plasma (PRP) with Tressfix Serum in treating chronic TE and to evaluate the impact on microRNA expression related to this condition. Methods: Patients including both male and females of aged between 20-40 years diagnosed with TE were included. Patients with scalp-specific dermatological illnesses, such as psoriasis or seborrheic dermatitis, were excluded. PRP was prepared using a double spin process and injected intradermally at designated scalp sites. Patients underwent a total of seven treatment sessions over a 14-week period Results: The study demonstrated a significant improvement in hair regrowth and reduction in hair shedding among participants following PRP therapy. All miRNA expression was significantly reduced in group A and group B where as in group C five out of nine miRNA expresses no significant p>0.05 mean difference. The expression levels of hsa-mir-223 were considerably lower in Group A (PRP and Tressfix serum combined) (113.53±2.95) compared to Group B (PRP alone, 140.21±5.56) and Group C (Tressfix serum alone, 163.22±2.37). The expression of hsa-mir-212 was also less in Group A (53.5±7.56) than in Group B (75.58±8.71) and Group C (87.12±6.9). These variations in expression imply that the combination strategy of PRP and Tressfix serum may have a more significant impact on lowering microRNA expression linked to TE than either therapy alone. Conclusion: The study underscores the importance of patient selection criteria and meticulous technique in optimizing treatment outcomes. Further research is warranted to elucidate the long-term efficacy and durability of PRP therapy in TE management.

Keywords: MicroRNAs, Platelet-Rich Plasma (PRP), Scalp, Telogen effluvium (TE), SALT scale